Company responds to reports that Sanofi is saying bye to Bangladesh

19 September 2019

Sanofi (Euronext: SAN) has provided an ambiguous response to reports that it is planning to move out of Bangladesh.

The French pharma major is set to wind up its operations in the Asian country after a presence dating back 60 years, according to reports in the local press.

Sanofi is considering then importing products back in to Bangladesh because its current arrangement is not making the firm competitive with domestic companies, which make medicines at lower prices, say the reports. The Paris-based firm, which does not make more affordable generic drugs, has not increased its manufacturing capacity in the country in recent years.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK